About this trial
Since 2002, Whooping cough surveillance in pediatric private practice has been set up in France. The results of the first years, 2002-2006, have confirmed the effectiveness of the Pertussis whole-cell (Pw) vaccine and in particular the duration of protection of 9/10 years. After evaluating cases in children vaccinated with Pw vaccines, the study aims today to analyze cases in children vaccinated with Pertussis acellular (Pa) vaccines used since 2002/2003 and to assess, on an outpatient basis, the impact of new vaccine recommendations in France (in 2013, introduction of a 2 + 1 schedule - 8 weeks, 4 months and a 11-month recall - and a 6-year recall, and in 2014, update in the recommendations of exams to be prescribed based on the child's age and vaccination status).
Eligibility criteria
Qualifiers
All children under 18 years old with a pertussis diagnosis is suspected and a biological exam is requested
Disqualifiers
children without symptoms with a household confirmed case
cases for which the pertussis diagnosis was not suspected by the pediatrician
Trial design
Treatments tested in this trial
- non interventional study
Treatment groups
Sponsors and collaborators
Association Clinique Thérapeutique Infantile du val de Marne
Lead sponsor
GlaxoSmithKline
Collaborator
Sanofi
Collaborator
Merck Sharp & Dohme LLC
Collaborator